| Index | — | P/E | — | EPS (ttm) | -2.76 | Insider Own | 7.47% | Shs Outstand | 43.81M | Perf Week | -4.36% |
| Market Cap | 1.56B | Forward P/E | 51.17 | EPS next Y | 0.69 | Insider Trans | 0.32% | Shs Float | 38.88M | Perf Month | -8.26% |
| Enterprise Value | 1.29B | PEG | — | EPS next Q | 0.11 | Short Float | 13.79% | Perf Quarter | 17.99% | ||
| Income | -123.00M | P/S | 2.54 | EPS this Y | 50.14% | Short Ratio | 5.86 | Perf Half Y | 46.12% | ||
| Sales | 614.00M | P/B | 1.03 | EPS next Y | 45.50% | ROA | -6.55% | Short Interest | 5.36M | Perf YTD | 6.89% |
| Book/sh | 34.47 | P/C | 4.78 | EPS next 5Y | 54.47% | ROE | -7.56% | 52W High | 46.41 -23.40% | Perf Year | 18.90% |
| Cash/sh | 7.44 | P/FCF | 155.74 | EPS past 3/5Y | — | ROIC | -1.01% | 52W Low | 15.93 123.16% | Perf 3Y | -25.69% |
| Dividend Est. | — | EV/EBITDA | — | Sales past 3/5Y | 2.29% 8.83% | Gross Margin | 44.05% | Volatility | 6.76% 6.50% | Perf 5Y | -67.63% |
| Dividend TTM | — | EV/Sales | 2.09 | EPS Y/Y TTM | — | Oper. Margin | -3.49% | ATR (14) | 2.27 | Perf 10Y | 170.34% |
| Dividend Ex-Date | Dec 02, 2021 | Quick Ratio | 2.21 | Sales Y/Y TTM | 4.96% | Profit Margin | -20.02% | RSI (14) | 46.53 | Recom | 2.42 |
| Dividend Gr. 3/5Y | 0.00% 0.00% | Current Ratio | 2.50 | EPS Q/Q | -180.00% | SMA20 | -4.56% | Beta | 1.46 | Target Price | 43.00 |
| Payout | 0.00% | Debt/Eq | 0.04 | Sales Q/Q | 11.81% | SMA50 | 1.77% | Rel Volume | 1.00 | Prev Close | 39.06 |
| Employees | 2,900 | LT Debt/Eq | 0.04 | Earnings | Nov 10 | SMA200 | 25.41% | Avg Volume | 960.07K | Price | 35.55 |
| IPO Date | Feb 02, 1995 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -132.56% -2.48% | Net Debt/EBITDA | — | Volume | 957,444 | Change | -8.99% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Feb-05-26 | Reiterated | Evercore ISI Group | Outperform | $50 → $45 |
| Jan-05-26 | Upgrade | Evercore ISI Group | In Line → Outperform | $33 → $50 |
| Dec-19-25 | Reiterated | Needham | Buy | $78 → $44 |
| Nov-25-25 | Reiterated | Raymond James | Outperform | $45 |
| Oct-30-25 | Upgrade | Jefferies | Hold → Buy | $64 → $38 |
| Aug-06-25 | Upgrade | Raymond James | Market Perform → Outperform | |
| Aug-05-25 | Reiterated | Evercore ISI Group | In Line | $62 → $33 |
| Dec-18-24 | Upgrade | Stephens & Co. | Equal Weight → Overweight | |
| Apr-04-24 | Reiterated | Jefferies | $64 | |
| May-10-23 | Downgrade | Keybanc | Overweight → Sector Weight |
Azenta, Inc. is a global leader specializing in advanced solutions for the discovery, handling, and preservation of life science samples. The company's operations span across North America, Europe, Asia Pacific (including China), and other international markets. Its business is structured into two main reportable segments: Life Sciences Products and Life Sciences Services. The Life Sciences Products division supplies sophisticated automated systems for the cold storage of chemical compounds and biological specimens. This segment also provides crucial equipment for sample preparation and manipulation, along with various consumables and specialized instruments that empower customers to effectively manage samples throughout their entire research and development workflows. Conversely, the Life Sciences Services segment offers a comprehensive suite of programs for sample management, integrated cold chain logistics, cutting-edge informatics, and a range of sample-centric laboratory services. These offerings are vital for propelling scientific research and accelerating drug development. Key services include secure sample banking, advanced genomic sequencing, gene synthesis, laboratory processing, detailed laboratory analysis, biospecimen acquisition, and other essential support functions. Azenta caters to a diverse client base within the life sciences sector, encompassing pharmaceutical companies, biotechnology firms, biorepositories, and academic or private research institutions. Established in 1978, the company, originally known as Brooks Automation, Inc., officially became Azenta, Inc. in December 2021. Its corporate headquarters are located in Chelmsford, Massachusetts.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 9/30/2025 | FY 2024 9/30/2024 | FY 2023 9/30/2023 | FY 2022 9/30/2022 | FY 2021 9/30/2021 | FY 2020 9/30/2020 | FY 2019 9/30/2019 | FY 2018 9/30/2018 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 614 | 594 | 573 | 665 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 344 | 324 | 319 | 432 | — | — | — | — | — | |
| Gross Profit | 270 | 270 | 255 | 233 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 255 | 251 | 253 | 281 | — | — | — | — | — | |
| Research and Development | 35 | 30 | 32 | 34 | — | — | — | — | — | |
| Other Operating Expense | 2 | 1 | 0 | 0 | — | — | — | — | — | |
| Operating Income | -21 | -11 | -30 | -82 | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | -131 | 4 | 11 | 52 | — | — | — | — | — | |
| Net Income Before Taxes | -152 | -7 | -19 | -30 | — | — | — | — | — | |
| Income Taxes | -40 | -32 | 5 | -18 | — | — | — | — | — | |
| Consolidated Net Income | -123 | -56 | -165 | -14 | — | — | — | — | — | |
| Net Income From Continuing Operations | -112 | 24 | -24 | -13 | — | — | — | — | — | |
| Net Income | -123 | -56 | -165 | -14 | — | — | — | — | — | |
| EPS (Recurring) | -2.75 | -1.22 | -3.09 | -0.22 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -2.75 | -1.22 | -3.09 | -0.22 | — | — | — | — | — | |
| EPS (Diluted) | -2.76 | -1.22 | -3.09 | -0.22 | — | — | — | — | — | |
| EBITDA | -96 | 54 | 72 | 55 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 2.61 | 2.22 | 4.48 | 4.98 | — | — | — | — | — | |
| Gross Margin | 43.97 | 45.45 | 44.50 | 35.04 | — | — | — | — | — | |
| Operating Margin | -3.42 | -1.85 | -5.24 | -12.33 | — | — | — | — | — | |
| Net Margin | -20.03 | -9.43 | -28.80 | -2.11 | — | — | — | — | — | |
| Shares Outstanding | 45 | 46 | 53 | 66 | — | — | — | — | — | |
| Market Capitalization | 1,600 | 1,321 | 2,567 | 3,313 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Starr Ephraim | SVP, Gen Counsel & Secretary | Jul 31 '26 | Buy | 24.17 | 335 | 8,096 | 68,728 | Aug 04 |
| Cornog William L | Director | May 18 '26 | Buy | 16.38 | 10,000 | 163,800 | 19,703 | May 19 |
| Cornog William L | Director | May 20 '25 | Buy | 27.37 | 2,748 | 75,213 | 25,795 | Nov 25 |
| Cornog William L | Director | May 19 '25 | Buy | 26.98 | 4,152 | 112,021 | 23,047 | Nov 25 |
| Cornog William L | Director | May 16 '25 | Buy | 26.50 | 100 | 2,650 | 18,895 | Nov 25 |
| Pirogova Olga | SVP and CHRO | Aug 12 '25 | Sale | 28.54 | 1,085 | 30,966 | 18,288 | Nov 14 |
| Zhou Ginger | SVP and GM, Multiomics | Aug 12 '25 | Sale | 28.54 | 1,085 | 30,966 | 26,831 | Nov 14 |
| Marotta John | President and CEO | Jun 02 '25 | Buy | 25.99 | 1,000 | 25,990 | 107,296 | Nov 14 |
| Malus Alan J | Director | May 30 '25 | Buy | 26.65 | 12,000 | 319,800 | 17,035 | Nov 14 |
| Marotta John | President and CEO | Sep 10 '25 | Sale | 29.41 | 316 | 9,294 | 105,980 | Sep 12 |
| Lin Lawrence Y. | EVP, CFO and Treasurer | Aug 11 '25 | Buy | 27.96 | 2,500 | 69,900 | 46,013 | Aug 12 |
| Hughes Violetta | VP, Chief Accounting Officer | Feb 03 '25 | Sale | 52.97 | 317 | 16,791 | 9,603 | Feb 04 |
| Zhou Ginger | SVP and General Manager, Genom | Jan 31 '25 | Buy | 45.88 | 417 | 19,132 | 27,916 | Feb 04 |
| Cueto Herman | EVP, Chief Financial Officer | Nov 19 '24 | Sale | 40.07 | 712 | 28,530 | 23,892 | Nov 21 |
| Hughes Violetta | VP, Chief Accounting Officer | Nov 19 '24 | Sale | 40.07 | 163 | 6,531 | 9,920 | Nov 21 |